A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer (CLEOPATRA) (CLEOPATRA)

Clinical Trial ID NCT00567190

PubWeight™ 67.85‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00567190

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2011 12.45
2 Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009 6.28
3 Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015 4.97
4 Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2011 4.12
5 Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013 3.87
6 Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol 2012 3.10
7 Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol 2014 2.72
8 Antibody-based therapeutics to watch in 2011. MAbs 2011 2.00
9 Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. J Clin Oncol 2015 1.99
10 Antibodies to watch in 2010. MAbs 2010 1.90
11 Targeting the ERBB family in cancer: couples therapy. Nat Rev Cancer 2013 1.72
12 Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. Oncologist 2013 1.35
13 Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treat Rev 2012 1.23
14 Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Ann Oncol 2014 1.19
15 Targeted therapy for HER2 positive breast cancer. J Hematol Oncol 2013 1.19
16 Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer. Br J Cancer 2012 1.12
17 Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer. J Surg Sci 2013 1.10
18 Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. Ann Oncol 2013 1.08
19 CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer. Clin Breast Cancer 2010 1.08
20 Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. Ann Oncol 2011 1.00
21 PI3K inhibitors as new cancer therapeutics: implications for clinical trial design. Onco Targets Ther 2016 0.96
22 Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials. BMC Med 2014 0.96
23 Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer. Biochim Biophys Acta 2014 0.96
24 A growing family: adding mutated Erbb4 as a novel cancer target. Cell Cycle 2010 0.95
25 Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA. Oncologist 2014 0.95
26 Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer. Int J Breast Cancer 2012 0.92
27 Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy. Future Oncol 2012 0.88
28 Back to the future: recombinant polyclonal antibody therapeutics. Curr Opin Chem Eng 2013 0.86
29 Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). Breast Cancer Res Treat 2013 0.81
30 Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. Lancet Oncol 2016 0.79
31 Ligand-based receptor tyrosine kinase partial agonists: New paradigm for cancer drug discovery? Expert Opin Drug Discov 2011 0.79
32 Targeted Therapies in HER2-Positive Breast Cancer - a Systematic Review. Breast Care (Basel) 2015 0.77
33 New clinical advances in immunotherapy for the treatment of solid tumours. Immunology 2015 0.76
34 Monoclonal antibodies and Fc fragments for treating solid tumors. Biologics 2012 0.75
35 Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies. Ther Adv Med Oncol 2016 0.75
36 Novel combinations for the treatment of metastatic breast cancer. Cancers (Basel) 2010 0.75
37 Optimal management of breast cancer in the elderly patient: current perspectives. Clin Interv Aging 2015 0.75
38 Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients. Breast Cancer (Dove Med Press) 2014 0.75
Next 100